No profile data available.
BridgeBio Pharma, Inc. (BBIO) is a healthcare company in the additional hormone and metabolic drugs industry, based in Palo Alto, United States, with about 999 full-time employees.
It reported revenue of $502.08 million for fiscal year 2025, up 126.3% from fiscal year 2024, and net income of -$724.93 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $243.68 million, up 120.4% from a year before. United States was its largest region in fiscal year 2025, with 72% of revenue. Its market capitalization was $12.78 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases.
BridgeBio Pharma reported $502.08 million in revenue for fiscal year 2025, up 126.3% from $221.90 million in fiscal year 2024. In Q2 2026 revenue was $243.68 million.
United States: 72% of revenue by region in fiscal year 2025, followed by Europe, Middle East, and Africa (25%).
$12.78 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (additional hormone and metabolic drugs) include Alnylam Pharmaceuticals, Inc. (ALNY), Corcept Therapeutics Incorporated (CORT), Amylyx Pharmaceuticals, Inc. (AMLX), MBX Biosciences, Inc. (MBX).